FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study)

We planned a multicenter randomized phase III study to evaluate the efficacy of appropriate dose of bevacizumab (5 or 10 mg/kg) with FOLFIRI in patients with advanced/metastatic colorectal cancer who have failed prior bevacizumab plus oxaliplatin-based therapy. The primary endpoint is progression-fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Mishima, Hideyuki, Oba, Koji, Sakamoto, Junichi, Muro, Kei, Yoshino, Takayuki, Hyodo, Ichinosuke, Maehara, Yoshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Clinical Trial Notes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3268463/
https://www.ncbi.nlm.nih.gov/pubmed/22167662
http://dx.doi.org/10.1093/jjco/hyr180
_version_ 1782222377226076160
author Mishima, Hideyuki
Oba, Koji
Sakamoto, Junichi
Muro, Kei
Yoshino, Takayuki
Hyodo, Ichinosuke
Maehara, Yoshihiko
author_facet Mishima, Hideyuki
Oba, Koji
Sakamoto, Junichi
Muro, Kei
Yoshino, Takayuki
Hyodo, Ichinosuke
Maehara, Yoshihiko
author_sort Mishima, Hideyuki
collection PubMed
description We planned a multicenter randomized phase III study to evaluate the efficacy of appropriate dose of bevacizumab (5 or 10 mg/kg) with FOLFIRI in patients with advanced/metastatic colorectal cancer who have failed prior bevacizumab plus oxaliplatin-based therapy. The primary endpoint is progression-free survival. The secondary endpoints are the toxicity, response rate, time to treatment failure, overall survival, overall survival from the start of the first-line treatment and second progression-free survival (time duration from the initiation of the first-line treatment until progression after the protocol treatment). A total of 370 patients were considered to be appropriate for this trial.
format Online
Article
Text
id pubmed-3268463
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-32684632012-01-30 FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study) Mishima, Hideyuki Oba, Koji Sakamoto, Junichi Muro, Kei Yoshino, Takayuki Hyodo, Ichinosuke Maehara, Yoshihiko Jpn J Clin Oncol Clinical Trial Notes We planned a multicenter randomized phase III study to evaluate the efficacy of appropriate dose of bevacizumab (5 or 10 mg/kg) with FOLFIRI in patients with advanced/metastatic colorectal cancer who have failed prior bevacizumab plus oxaliplatin-based therapy. The primary endpoint is progression-free survival. The secondary endpoints are the toxicity, response rate, time to treatment failure, overall survival, overall survival from the start of the first-line treatment and second progression-free survival (time duration from the initiation of the first-line treatment until progression after the protocol treatment). A total of 370 patients were considered to be appropriate for this trial. Oxford University Press 2012-02 2011-12-12 /pmc/articles/PMC3268463/ /pubmed/22167662 http://dx.doi.org/10.1093/jjco/hyr180 Text en © The Author 2011. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Trial Notes
Mishima, Hideyuki
Oba, Koji
Sakamoto, Junichi
Muro, Kei
Yoshino, Takayuki
Hyodo, Ichinosuke
Maehara, Yoshihiko
FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study)
title FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study)
title_full FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study)
title_fullStr FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study)
title_full_unstemmed FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study)
title_short FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study)
title_sort folfiri plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase iii study (eagle study)
topic Clinical Trial Notes
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3268463/
https://www.ncbi.nlm.nih.gov/pubmed/22167662
http://dx.doi.org/10.1093/jjco/hyr180
work_keys_str_mv AT mishimahideyuki folfiriplusbevacizumab5mgkgversus10mgkgassecondlinetherapyinpatientswithmetastaticcolorectalcancerwhohavefailedfirstlinebevacizumabplusoxaliplatinbasedtherapyarandomizedphaseiiistudyeaglestudy
AT obakoji folfiriplusbevacizumab5mgkgversus10mgkgassecondlinetherapyinpatientswithmetastaticcolorectalcancerwhohavefailedfirstlinebevacizumabplusoxaliplatinbasedtherapyarandomizedphaseiiistudyeaglestudy
AT sakamotojunichi folfiriplusbevacizumab5mgkgversus10mgkgassecondlinetherapyinpatientswithmetastaticcolorectalcancerwhohavefailedfirstlinebevacizumabplusoxaliplatinbasedtherapyarandomizedphaseiiistudyeaglestudy
AT murokei folfiriplusbevacizumab5mgkgversus10mgkgassecondlinetherapyinpatientswithmetastaticcolorectalcancerwhohavefailedfirstlinebevacizumabplusoxaliplatinbasedtherapyarandomizedphaseiiistudyeaglestudy
AT yoshinotakayuki folfiriplusbevacizumab5mgkgversus10mgkgassecondlinetherapyinpatientswithmetastaticcolorectalcancerwhohavefailedfirstlinebevacizumabplusoxaliplatinbasedtherapyarandomizedphaseiiistudyeaglestudy
AT hyodoichinosuke folfiriplusbevacizumab5mgkgversus10mgkgassecondlinetherapyinpatientswithmetastaticcolorectalcancerwhohavefailedfirstlinebevacizumabplusoxaliplatinbasedtherapyarandomizedphaseiiistudyeaglestudy
AT maeharayoshihiko folfiriplusbevacizumab5mgkgversus10mgkgassecondlinetherapyinpatientswithmetastaticcolorectalcancerwhohavefailedfirstlinebevacizumabplusoxaliplatinbasedtherapyarandomizedphaseiiistudyeaglestudy

Ejemplares similares